Skip to content

Morphological and Metabolic Changes of Dorsal Root Ganglion and Sympathetic Ganglion in Patients With Postherpetic Neuralgia on MRI

Morphological and Metabolic Changes of Dorsal Root Ganglion and Sympathetic Ganglion in Patients With Postherpetic Neuralgia on MRI

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04880408
Enrollment
30
Registered
2021-05-10
Start date
2021-01-01
Completion date
2022-10-31
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathy;Peripheral, Pain

Keywords

herpes zoster, postherpetic neuralgia, MRI, dorsal root ganglion

Brief summary

Object: Postherpetic neuralgia (PHN) is pain that persists for 1-3 months after herpes zoster onset. It is the most common complication of herpes zoster and occurs in 15-40% of patients with herpes zoster. PHN has been suggested to be related with the lesion of doral root ganglion (DRG). However, the studies are almost limited to autopsies and animals , and the mechanism of PHN is still unclear. This study was conducted to investigate morphological and metabolic changes of DRG and sympathetic ganglion in patients with postherpetic neuralgia on MRI. Method: 30 patients diagnosed as PHN were recruited. The volume and fractional anisotropy of DRG of lesion dermatomes were measured under MRI, and compared with contralateral and adjacent DRG. The volume and fractional anisotropy of sympathetic ganglion of lesion dermatomes were also measured under MRI, and compared with contralateral and adjacent sympathetic ganglion.Then, the association between clinical phenotypes and DRG changes were analyzed.

Detailed description

Patients with the following conditions were excluded: psychiatric diseases or communication disorders; contraindications to MRI;DRG radiofrequency therapy, spinal cord electrical stimulation and other direct intervention treatments for DRG were performed before examination.

Interventions

None listed

Sponsors

Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* aged more than 18 herpes zoster in cervical, thoracic,lumbar or sacral regions agree to participate to the research

Exclusion criteria

* can not cooperate to MRI for mental disease contraindication for MRI treatments for DRG such as radiaofrequency therapy, spinal cord electircal stimulation were performed before examination. disagree to participate to the research

Design outcomes

Primary

MeasureTime frameDescription
To compare the volume and fractional anisotropy of DRG between lesion dermatomes and contralateral dermatomes1 yearDRGs of lesion and contralateral dermatomes were scanned under MRI. Then, the valume (the maximum cross-section area ×layers/2) and fractional anisotropy of DRGs were measured with RadiAnt DICOM Viewer, and the comparison was made between lesion and contralateral DRG.

Secondary

MeasureTime frameDescription
To compare the volume and fractional anisotropy of sympathetic ganglion between lesion dermatomes and contralateral dermatomes.1 yearas primary outcome measure, sympathetic ganglions of lesion and contralateral dermatomes were scanned under MRI. Then, the valume (the maximum cross-section area ×layers/2) and fractional anisotropy of sympathetic ganglions were measured with RadiAnt DICOM Viewer, and the comparison was made between lesion and contralateral sympathetic ganglions.
To compare the volume and fractional anisotropy of DRG between lesion dermatomes and adjacent dermatomes.1 yearDRGs of lesion and adjacent dermatomes were scanned under MRI. Then, the valume (the maximum cross-section area ×layers/2) and fractional anisotropy of DRGs were measured with RadiAnt DICOM Viewer, and the comparison was made between lesion and adjacent DRG.

Countries

China

Contacts

Primary ContactXianwei Zhang, Doctor
znpain@sina.com(+86)13037154560

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026